To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05062980
Title Reqorsa (Quaratusugene Ozeplasmid) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (Acclaim-2)
Acronym Acclaim-2
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genprex, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Moffitt Cancer Center - Magnolia Campus Tampa Florida 33612 United States Details
Ochsner Clinic Foundation New Orleans Louisiana 70121 United States Details
Washington University School of Medicine - Siteman Cancer Center Saint Louis Missouri 63110 United States Details
The Valley Hospital - Luckow Pavilion Paramus New Jersey 07652 United States Details
Mary Crowley Cancer Research Dallas Texas 75230 United States Details
Millennium Oncology Houston Texas 77090 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field